Activated protein C resistance and the FV:R506Q mutation in a random population sample

Thrombosis and Haemostasis

Volumn 81, Issue 6, 1999, Pages 918-924

  Lowe, Gordon D O ^a   Rumley, Ann ^a   Woodward, Mark ^b   Reid, Evan ^c,d   Rumley, Joseph ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; MALE; NORMAL HUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; VEIN THROMBOSIS;

EID: 0033042108     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614599     Document Type: Article

References (47)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Nat Acad Sci 1993; 90: 1004-8.
2. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlbäck B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia. Thromb Haemost 1996; 76: 651-62 and 824-34.
3. Bertina RM. Laboratory diagnosis of resistance to activated protein C (APC-resistance). Thromb Haemost 1997; 78: 478-82.
4. 506Q mutation is a common risk factor for venous thrombosis. Thromb Haemost 1997; 78: 483-8.
5. Axelsson F, Rosén S. APC resistance: Product monograph. Mölndal, Sweden: Chromogenix AB, 1997.
6. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA. Reitsma PH. Mutation in blood coagulation factor V associated with resistance in activated protein C. Nature 1994; 369: 64-7.
7. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
8. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction (letter). Lancet 1994; 344: 1709-10.
9. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M. Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995; 73: 558-60.
10. Catto A, Carter A, Ireland H, Bayston TA, Philippou H, Barrett J, Lane DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995; 15: 783-5.
11. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong TVM, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-9.
12. Rosendaal FR, Siscovick DS, Schwartz SM, Beverley RK, Psaty BM, Longstrength WT, Raghernathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997; 89: 2817-21.
13. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolys 1996; 7: 1-6.
14. O'Donnell J, Tuddenham EGD, Manning R, Kemball-Cook G, Johnson D, Laffan M. High prevalence of elevated Factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationships to the acute phase reaction. Thromb Haemost 1997; 77: 825-8.
15. Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997; 97: 775-84.
16. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H, Philippou H, Lane DA, Morrison CE. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1997; 97: 785-97.
17. Lowe GDO, Rumley A, Woodward M, Reid E. Oral contraceptives and venous thromboembolism (letter). Lancet 1997; 349: 1623.
18. World Health Organization Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988; 41: 105-13.
19. Beauchamp NJ, Daly ME, Cooper PC, Preston FE, Peake IR. Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet 1994; 344: 694-5.
20. Woodward M, Laurent K, Tunstall-Pedoe H. An analysis of risk factors for prevalent coronary heart disease by using the proportional odds model. The Statistician 1995; 44: 69-80.
21. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
22. 506 mutation - evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis. Thromb Haemost 1997; 77: 436-9.
23. Korsan-Bengtsen K, Wilhelmsen L, Tibblin G. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. I. Correlations between the variables of clotting and fibrinolysis. Thromb Diath Haemorr 1972; 28: 89-98.
24. Korsan-Bengtsen K, Wilhelmsen L, Tibblin G. Blood coagulation and fibrinolysis in a random sample of 788 men 54 years old. II. Relations of the variables to 'risk factors' for myocardial infarction. Thromb Diath Haemorr 1972; 28: 99-108.
25. Henkens CMA, Bom VJJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII clotting activity. Thromb Haemost 1995; 74: 1198-9.
26. Thomson JM, Poller L. The activated partial thromboplastin time. In: Thomson JM (ed). Blood Coagulation and Haemostasis: A Practical Guide, 3rd edn. Edinburgh: Churchill Livingstone 1985: 301-39.
27. Cawkwell RD. Patient's age and the activated partial thromboplastin time test. Thromb Haemost 1978; 39: 780-1.
28. Henkens CMA, Bom VJJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
29. Østerud B, Robertson R, Asvarg GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coagul Fibrinolys 1994; 5: 853-4.
30. Olivieri O, Friso S, Manzato F, Guella A, Bernardi F, Lunghi B, Girelli D, Azzini M, Brocco G, Russi G, Cortocher R. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
31. Meade TW. Hormone replacement therapy and haemostatic function. Thromb Haemost 1997; 78: 765-9.
32. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost 1997; 78: 770-80.
33. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993; 328: 1069-75.
34. Balendra R. Deep vein thrombosis of the leg: natural history and haemostatic variables. MD Thesis, University of Belfast, 1990.
35. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
36. 506 Arg to Gln mutation. Thromb Haemost 1995; 73: 731-2.
37. Faioni EM, Franchi F. Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-71.
38. Greenford JS, Eichinger S, Griffin JH, Bauer KA. Variability of thrombosis among homozygous siblings with resistance to activated protein C due to an Arg to Gln mutation in the gene for factor V. N Engl J Med 1994; 331: 1559-62.
39. Simioni P, Scarano L, Gavasso S, Sardella C, Girolami B, Scudeller A, Girolami A. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-41.
40. 506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
41. Martinelli I, Boltasso B, Duca F, Faioni E, Mannucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-5.
42. Kakkar VV, Howe CT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg - is there a 'high risk' group. Am J Surg 1970; 120: 527-30.
43. Nicolaides AN, Irving D. Clinical factors and the risk of deep vein thrombosis. In: Nicolaides AN, ed. Thromboembolism. Aetiology, advances in prevention and management. Lancaster: Medical and Technical Publishing, 1975: 193-204.
44. Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976; ii: 910-2.
45. Lowe GDO, Osborne DH, McArdle BM, Smith A, Carter DC, Forbes CD, McLaren D, Prentice CRM. Prediction and selective prophylaxis of venous thrombosis in elective gastrointestinal surgery. Lancet 1982; i: 409-12.
46. Goldhaber SZ, Savage DD, Garrison RJ, Castelli WP, Kannel WB, McNamara PM, Gherardi G, Feinleib M. Risk factors for pulmonary embolism: the Framingham Study. Am J Med 1983; 74: 1023-8.
47. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997; 78: 1-6.